Korro Bio Inc. Common Stock (KRRO)
Stock · NASDAQ · Health Care
$8.7as of 10/16/2026
Price chart
Active signals
KRRO Signal Track Record
How signals performed across all stocks →What KRRO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 28 | -2.6% | 46% | September 8, 2026 |
| Bollinger Band BreakdownActive now | 21 | -5.7% | 43% | September 18, 2026 |
| Bollinger Band Breakout | 20 | +12.3% | 65% | April 2, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -5.8% | 25% | August 7, 2026 |
| Any 20-session window (baseline) | -3.2% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About KRRO
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA ed…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 57
- Website
- www.korrobio.com/
Fundamentals
- 1-day range
- $8.53$9.78
- Market cap
- $174.80M
- P/E (trailing)
- —
- P/E (forward)
- -2.11
- EPS (trailing)
- $-10.00
- Dividend yield
- —
- Beta
- 3.28
- Avg. volume
- 148.0K
How Korro Bio Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
10 analyst ratings
Korro Bio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- KRROKorro Bio Inc. Common Stock$8.49▼ 8.81%Market cap $174.80MP/E —$5.2$55.89
- ARCTArcturus Therapeutics Holdings Inc. Common Stock$10.34▼ 8.25%Market cap $172.81MP/E —$5.5$24.17
- ORMPOramed Pharmaceuticals Inc. Common Stock$4.07▼ 2.63%Market cap $178.87MP/E 0.98$2.09$5.47
- DERMJourney Medical Corporation Common Stock$4.97▼ 3.12%Market cap $179.80MP/E —$4.31$9.56
- CRBPCorbus Pharmaceuticals Holdings Inc. Common Stock$4.52▲ 4.39%Market cap $180.46MP/E —$4.37$20.56
- OKUROnKure Therapeutics Inc. Class A Common Stock$2.1▼ 1.41%Market cap $168.06MP/E —$2.13$5.38
- LFCRLifecore Biomedical Inc. Common Stock$6.38▼ 0.93%Market cap $181.55MP/E —$3.63$8.98
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KRRO Korro Bio Inc. Common Stock | $174.80M | — | $8.49 | ▼ 8.81% | $5.2$55.89 |
| ARCT Arcturus Therapeutics Holdings Inc. Common Stock | $172.81M | — | $10.34 | ▼ 8.25% | $5.5$24.17 |
| ORMP Oramed Pharmaceuticals Inc. Common Stock | $178.87M | 0.98 | $4.07 | ▼ 2.63% | $2.09$5.47 |
| DERM Journey Medical Corporation Common Stock | $179.80M | — | $4.97 | ▼ 3.12% | $4.31$9.56 |
| CRBP Corbus Pharmaceuticals Holdings Inc. Common Stock | $180.46M | — | $4.52 | ▲ 4.39% | $4.37$20.56 |
| OKUR OnKure Therapeutics Inc. Class A Common Stock | $168.06M | — | $2.1 | ▼ 1.41% | $2.13$5.38 |
| LFCR Lifecore Biomedical Inc. Common Stock | $181.55M | — | $6.38 | ▼ 0.93% | $3.63$8.98 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Targetbenzinga · 10/6/2026
- HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price TargetBenzinga · 10/6/2026
- Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121Yahoo · 10/5/2026
- Korro Bio Doses First First Group Of Patients In Its Phase 1/2 Clinical Study Of KRRO-121 To Treat Hyperammonemia In Patients With Urea Cycle DisordersBenzinga · 10/5/2026
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · 9/18/2026
- Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 9/11/2026
Insider Activity
Insider Actions →- FORMELA JEAN FRANCOIS · September 14, 2026 · Sale6.6K @ $14.12
- FORMELA JEAN FRANCOIS · September 14, 2026 · Sale31.9K @ $14.12
- Dolan Oliver · September 11, 2026 · Sale5 @ $13.72
- FORMELA JEAN FRANCOIS · September 11, 2026 · Sale1.8K @ $13.99
- FORMELA JEAN FRANCOIS · September 11, 2026 · Sale8.4K @ $13.99
- Dolan Oliver · September 9, 2026 · Sale6 @ $13.6
- Dolan Oliver · September 8, 2026 · Sale7.3K @ $13.51
- FORMELA JEAN FRANCOIS · August 26, 2026 · Sale51 @ $13.96
- FORMELA JEAN FRANCOIS · August 26, 2026 · Sale249 @ $13.96
- FORMELA JEAN FRANCOIS · August 19, 2026 · Sale4.9K @ $14
- FORMELA JEAN FRANCOIS · August 19, 2026 · Sale23.6K @ $14
- FORMELA JEAN FRANCOIS · August 11, 2026 · Sale368 @ $13.96
- FORMELA JEAN FRANCOIS · August 11, 2026 · Sale1.8K @ $13.96
- Lynx1 Capital Management LP · August 10, 2026 · Buy1.5K @ $13.19
- Lynx1 Capital Management LP · August 6, 2026 · Buy5.2K @ $11.4
Institutional Ownership
March 31, 2026
- Total shares held
- 12.92M
- Total value held
- $145.41M
- Institutional holders
- 94
- Unknown1.54M
- Unknown1.30M
- Unknown1.14M
- Unknown1.04M
- Unknown1.01M
- Unknown706.9K
- Unknown660.0K
- Unknown540.1K
- Unknown460.0K
- Unknown450.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Korro Bio Begins Phase 1/2 Trial for KRRO-121
Korrr Bio has begun dosing the first cohort of its Phase 1/2 study for KRRO-121, a therapy aimed at treating hyperammonemia in patients with urea cycle disorders. The initiation of this trial marks a significant milestone in the drug’s development timeline. Analysts continue to hold a $15 price target, reflecting confidence in the program. Current technical data shows the stock trading near its 52‑week low with an RSI of 39.7.
Korro Bio Begins Phase 1/2 Trial for KRRO-121. Korrr Bio has begun dosing the first cohort of its Phase 1/2 study for KRRO-121, a therapy aimed at treating hyperammonemia in patients with urea cycle disorders. The initiation of this trial marks a significant milestone in the drug’s development timeline. Analysts continue to hold a $15 price target, reflecting confidence in the program. Current technical data shows the stock trading near its 52‑week low with an RSI of 39.7.